Quick Answer
Oaktree Acquisition Corp. III Life Sciences reported Cash and Equivalents of $1.43 million for fiscal year 2025.
Oaktree Acquisition Corp. III Life Sciences Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.43M | +5.7% |
| 2024 | $1.36M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.33M | — | -4.1% |
| June 30, 2025 | $1.39M | — | +8.1% |
| March 31, 2025 | $1.28M | — | -5.6% |
| December 31, 2024 | $1.36M | — | — |
- Oaktree Acquisition Corp. III Life Sciences showed an increase of +5.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, Oaktree Acquisition Corp. III Life Sciences’s cash and equivalents has grown by 5.7% (from $1.36 million to $1.43 million).
- The most recent figure is from Oaktree Acquisition Corp. III Life Sciences’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: